Recombinant Human KGF/FGF-7 GMP Protein, CF

The bioactivity of Recombinant Human KGF/FGF‑7 GMP Protein (Catalog # BT-KGF-GMP) was measured in a cell proliferationassay using Ba/F3 mouse pro B cells transfected with human FGF RIIb. The ED50 for this effect is 6.00 ‑ 60.0 ng/mL. Threeindependent lots were tested for bioactivity and plotted on the same graph to show lot-to-lotconsistency of GMP KGF/FGF‑7 protein.

Equivalent bioactivity of GMP(Catalog # BT-KGF-GMP) andAnimal-Free (BT-KGF-AFL) grades of RecombinantHuman KGF/FGF-7 measured in a cell proliferationassay using Ba/F3 mouse pro Bcells transfected with human FGFRIIb (orange and green, respectively).

2 μg/lane of Recombinant Human KGF/FGF‑7 GMP Protein (Catalog # BT-KGF-GMP) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 20 kDa, under reducing conditions.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human KGF/FGF-7 GMP Protein, CF Summary

• Details of Functionality: Measured in a cell proliferation assay using Ba/F3 mouse pro B cells transfected with human FGF RIIb. The ED₅₀ for this effect is 6.00-60.0 ng/mL.
  The specific activity of recombinant human KGF/FGF-7 is >8.16 x 10⁵ units/mg, which is calibrated against the human KGF/FGF-7 WHO Standard (NIBSC code: 03/150).
• Source: E. coli-derived human KGF/FGF-7 protein
  Cys32 - Thr194, with an N-terminal Met
  Produced using non-animal reagents in an animal-free laboratory.
  Manufactured and tested under cGMP guidelines.
• Accession #: P21781.1
• N-terminal Sequence: (Cys)₃₂-Asn-Asp-Met-Thr-Pro-Glu-Gln-Met-Ala
  Asn₃₃-Asp-Met-Thr-Pro-Glu-Gln-Met-Ala-Thr
• Protein/Peptide Type: GMP Recombinant Proteins
• Purity: >97%, by SDS-PAGE with quantitative densitometry by Coomassie® Blue Staining. The molecular weight by mass spectrometry is 18927 Da ± 61 Da
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 19 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 20 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • A minimum of 12 months when stored at ≤ -20 °C as supplied. Refer to lot specific COA for the Use by Date.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in MOPS, Na₂SO₄ and EDTA with Trehalose.
• Purity: >97%, by SDS-PAGE with quantitative densitometry by Coomassie® Blue Staining. The molecular weight by mass spectrometry is 18927 Da ± 61 Da
• Reconstitution Instructions: Reconstitute at 500 μg/mL in sterile water.

Notes

END USER TERMS OF USE OF PRODUCT

The following terms are offered to you upon your acceptance of these End User Terms of Use of Product. By using this product, you indicate your acknowledgment and agreement to these End User Terms of Use of Product. If you do not agree to be bound by and comply with all of the provisions of these End User Terms of Use of Product, you should contact your supplier of the product and make arrangements to return the product.

We suggest you print and retain a copy of these End User Terms of Use of Product for your records.

The End User is aware that R&D Systems, Inc. sells GMP products for preclinical or clinical ex vivo use and not for in vivo use. The End User further agrees, as a condition of the sale of R&D Systems' GMP products that: a) the End User will not use this GMP Product in any procedure wherein the product may be directly or indirectly administered to humans, unless the End User has obtained, or prior to their use will have obtained, an Investigational New Drug (IND) exemption from the FDA and will use the product only in accordance with the protocols of such IND and of the Institutional Review Board overseeing the proposed research, or b) the End User will use the products outside of the United States in accordance with the protocols of research approved by the Institutional Review Board or authorized ethics committee and regulatory agencies to which the End User is subject to in their territory.

R&D Systems, Inc. has the right, at its sole discretion, to modify, add or remove any terms or conditions of these End User Terms of Use without notice or liability to you. Any changes to these End User Terms of Use are effective immediately following the printing of such changes on this product insert. The most recent version of these End User Terms of Use of Product may be found at: RnDSystems.com/Legal.

You agree to review these End User Terms of Use of Product to ensure any subsequent use by you of R&D Systems' GMP Products following changes to these End User Terms of Use of Product constitutes your acceptance of all such changes.

 

TERMS AND CONDITIONS

The following limitation applies to R&D Systems' warranty and liability for damages: All products are warranted to meet R&D Systems' published specifications when used under normal laboratory conditions.

R&D SYSTEMS DOES NOT MAKE ANY OTHER WARRANTY OR REPRESENTATION WHATSOEVER, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO ITS PRODUCTS. IN PARTICULAR, R&D SYSTEMS DOES NOT MAKE ANY WARRANTY OF SUITABILITY, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE.

NOTWITHSTANDING ANY OTHER PROVISIONS OF THESE TERMS AND/OR ANY OTHER AGREEMENT BETWEEN R&D SYSTEMS AND PURCHASER FOR THE PURCHASE OF THE PRODUCTS, R&D SYSTEMS' TOTAL LIABILITY TO PURCHASER ARISING FROM OR IN RELATION TO THESE TERMS, AN AGREEMENT BETWEEN THE PARTIES OR THE PRODUCTS, WHETHER ARISING IN CONTRACT, TORT OR OTHERWISE SHALL BE LIMITED TO THE TOTAL AMOUNT PAID BY PURCHASER TO R&D SYSTEMS FOR THE APPLICABLE PRODUCTS. IN NO EVENT WILL R&D SYSTEMS BE LIABLE FOR THE COST OF PROCUREMENT OF SUBSTITUTE GOODS.

Full details of R&D Systems' Terms and Conditions of Sale can be found online at: RnDSystems.com/Legal.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human KGF/FGF-7 GMP Protein, CF

• FGF7
• FGF-7
• fibroblast growth factor 7HBGF-7
• HBGF7
• HBGF-7
• Heparin-binding growth factor 7
• keratinocyte growth factor
• KGF
• KGFfibroblast growth factor 7 (keratinocyte growth factor)

Background

Keratinocyte Growth Factor (KGF), or Fibroblast Growth Factor-7 (FGF-7), is an important component in many cell culture protocols. It is widely used to promote the growth and differentiation of epithelial cells, including skin keratinocytes, and lung, corneal, and intestinal epithelia. It is a part of tissue engineering and organoid culture protocols, where it can enhance the generation of complex tissues such as liver, gastrointestinal tract, lung, and mammary gland. Furthermore, KGF/FGF-7 has been shown to stimulate the proliferation of pancreatic endocrine progenitor cells and promote their differentiation into mature insulin-secreting beta cells. In these capacities KGF/FGF-7 has significant clinical relevance in studies to better understand gastrointestinal disorders, wound healing, respiratory disease, and diabetes.

Bioinformatics

• Uniprot:
  • P21781.1()